- Home
- ROIV vs CWAN Comparison
ROIV vs CWAN Comparison
Compare ROIV & CWAN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ROIV | CWAN |
|---|---|---|
| Founded | 2014 | 2004 |
| Country | United Kingdom | United States |
| Employees | N/A | 1915 |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.1B | 7.1B |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | ROIV | CWAN |
|---|---|---|
| Price | $22.21 | $24.10 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 8 | 11 |
| Target Price | $24.31 | ★ $29.12 |
| AVG Volume (30 Days) | 8.2M | ★ 11.5M |
| Earning Date | 02-09-2026 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 46826.67 |
| EPS | N/A | ★ 1.40 |
| Revenue | $20,329,000.00 | ★ $640,376,000.00 |
| Revenue This Year | N/A | $64.93 |
| Revenue Next Year | $741.42 | $29.40 |
| P/E Ratio | ★ N/A | $17.23 |
| Revenue Growth | N/A | ★ 50.91 |
| 52 Week Low | $8.73 | $15.74 |
| 52 Week High | $23.47 | $32.00 |
Technical Indicators
Market Signals| Indicator | ROIV | CWAN |
|---|---|---|
| Relative Strength Index (RSI) | 58.09 | 73.00 |
| Support Level | $21.60 | $24.04 |
| Resistance Level | $22.72 | $24.28 |
| Average True Range (ATR) | 0.82 | 0.59 |
| MACD | -0.00 | 0.19 |
| Stochastic Oscillator | 61.77 | 94.75 |
Price Performance
Historical ComparisonAbout ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
About CWAN Clearwater Analytics Holdings Inc.
Clearwater Analytics describes its mission as aiming to be the world's most trusted and comprehensive technology platform for the entire investment cycle. Clearwater has historically focused on back-office functions such as investment accounting, but with acquisitions such Enfusion, Beacon, and Bistro, the firm has broadened its focus with front-office and middle-office capabilities. Clearwater primarily serves insurance companies, asset managers, hedge funds, and corporate treasuries. Pro forma for Enfusion, about 76% of Clearwater's revenue is generated in the US.